Dyne Therapeutics Inc

NASDAQ:DYN  
9.27
+0.11 (+1.20%)
Products, Regulatory

Dyne Therapeutics Announces Submission Of Ind Application To Initiate Clinical Trial Of Dyne-251 For Duchenne Muscular Dystrophy

Published: 12/02/2021 13:46 GMT
Dyne Therapeutics Inc (DYN) - Dyne Therapeutics Announces Submission of Ind Application to Initiate Clinical Trial of Dyne-251 for Duchenne Muscular Dystrophy.
Dyne Therapeutics Inc - Dyne-101 Ind Submission in Dm1 Expected in Q1 of 2022.
Dyne Therapeutics Inc - Initiation of Patient Dosing of Dyne-251 and Dyne-101 in Multiple Ascending Dose Clinical Trials Anticipated by Mid-2022.